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Abstract
Metastatic brain tumors are the most common brain tumors in adults. With numerous successful 
advancements in systemic treatment of most common cancer types, brain metastasis is becoming 
increasingly important in the overall prognosis of cancer patients. Brain metastasis of peripheral 
tumor is the result of complex interplay of primary tumor, immune system and central nervous 
system microenvironment. Once formed, brain metastases hide behind the blood brain barrier and 
become inaccessible to chemotherapies that are otherwise successful in targeting systemic cancer. 
The approval of immune checkpoint inhibitors for several common cancers such as advanced 
melanoma and lung cancers brings with it the opportunity and obligation to further understand the 
mechanisms of immunosuppression by tumors that spread to the brain as well as the interaction 
between the brain environment and tumor microenvironment. In this review paper we define the 
central role of the immune system in the development of brain metastases. We performed a 
comprehensive review of the literature to outline the molecular mechanisms of 
immunosuppression used by tumors and how the immune system interacts with the central nervous 
system to facilitate brain metastasis. In particular we discuss the tumor-type-specific mechanisms 
of metastasis of cancers that preferentially metastasize to the brain as well as the therapies that 
effectively modulate the immune response, such as immune checkpoint inhibitors and vaccines.
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Introduction
Brain metastases (BM) are the most common type of intracranial neoplasm in adults. It is 
estimated that in the United States 2.0% of all patients with newly diagnosed cancer have 
brain metastases at the time of diagnosis, with an annual incidence ranging from 21,000 to 
43,000 [1]. Autopsy studies have found that this may be a massive underestimation, and that 
up to one fourth of all cancer patients develop brain metastases before death, a total of 
150,000–200,000 annually [2,3]. Incidence of brain metastases has increased in recent years 
due to a combination of better diagnostic imaging and successful treatment modalities 
resulting in longer survival times after diagnosis of primary cancer [4]. According to a study 
of 15,517 patients in Sweden, which found the incidence of BM to double between 1987 and 
2006, the cancers most responsible for this increased incidence are breast in women and 
lung in both genders [5].
The presence of brain metastases can be a devastating development that significantly 
worsens the prognosis of patient’s primary cancer, and in many cases disqualifies them from 
various novel and cutting edge clinical trials. Median overall survival in patients with brain 
metastases left untreated is around 5 weeks [4]. Modern treatment modalities can extend this 
prognosis to 3–18 months, but multivariate analyses show that patients with brain metastases 
still carry an overall worse prognosis than their BM-free counterparts [4,6,7]. Not only do 
metastases to the brain worsen prognosis but they also have a negative impact on quality of 
life, eliciting CNS symptoms such as ataxia, seizures, visual and speech problems, 
headaches, and cognitive impairment [8]. To successfully and precisely treat metastatic brain 
tumors, it is of critical importance to understand the basic molecular mechanisms underlying 
the formation of brain metastases.
In the course of metastasis, cancer cells must break free from the constraints of their primary 
tumor, migrate into systemic circulation, survive in circulation, extravasate at their 
destination, and establish a new niche in a foreign environment; evading detection by the 
immune system throughout the process. In this review, we describe the role of immune 
system in metastatic progression, the unique microenvironment of brain metastases, how 
metastatic mechanisms differ between primary tumor types, and the current state of 
immunotherapies in the treatment of BMs.
Epidemiology
The most common primary tumor that metastasizes to the brain is that of the lung, 
specifically small cell lung cancers, with 15.8% of patients having brain metastases [1]. The 
next most common cancers are non-small cell lung cancers (12.8%), breast cancer (0.4%), 
renal cancer (1.5%), and melanoma (0.7%) [1]. Interestingly, among patients with metastatic 
disease, metastatic melanoma patients have the highest rate of brain metastases, reflecting its 
increased propensity to metastasize to the brain [1]. Prostate and breast cancer brain 
metastases have the best long-term prognoses, compared to colorectal, melanoma, and lung 
cancer metastases that have the worst prognosis (Table 1) [1].
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Improvements in treatment modalities have led to a gradual increase in the survival for 
patients with BMs. Whole-brain radiation therapy (WBRT) and corticosteroid treatment 
developed in the mid-twentieth century increased survival times from 4–6 weeks to 4–6 
months [2]. However it is associated with cognitive deficits, which results in significant 
impairment in the quality of life of long-term survivors. As a result, current practice patterns 
shifted away from use of WBRT to stereotactic radiosurgery (SRS) for oligo-metastasis, 
defined as limited number of BMs, reserving WBRT as salvage therapy or for disseminated 
BMs [9–12]. Advancements in neurosurgery led to the development of surgical resection as 
a treatment modality for patients with limited number of brain metastases, increasing the 
median survival times to 10–16 months [2]. The current role for neurosurgery is based on 
consensus guidelines and is supported by recent retrospective studies demonstrating 
improved local control and overall survival with the combination of surgery and SRS vs. 
SRS alone for larger brain metastases [13,14]. Modern research has turned towards 
immunotherapies, using immune checkpoint inhibitors to modulate the immune 
microenvironment, and cellular therapies to mount an effective response against the tumors. 
These therapies have shown, in some cases, to dramatically increase survival times in 
patients with BMs [15,16]. There is a real potential for these therapies to transform how we 
treat BMs, but they require a solid understanding of tumor microenvironment and how it 
may be manipulated.
Immune System and Progression of Metastasis
Stephen Paget first developed the seed and soil theory of metastasis in 1889. He observed a 
nonrandom pattern of metastases on autopsy in women with breast cancer and hypothesized 
that this was due to the metastatic cells, what he referred to as the “seeds,” having a greater 
proclivity for certain organs, the “soil” [17]. A greater understanding of mechanisms of 
metastasis has made clearer the requirements needed for a cell to free itself from the primary 
tumor’s constraints, enter the blood stream, survive in the blood stream, invade its 
destination organ, and then survive in that new environment (Figure 1). One common feature 
in each of these steps is the need for the metastatic cell to avoid recognition and destruction 
by the immune system at every step of metastatic progression. Immunosuppressive 
mechanisms are vital to the survival of the seed, and the immune system is a key driver in 
creating the fertile soil for these cells to take hold. It is important to understand these 
mechanisms in the context of brain metastases to design novel and targeted 
immunotherapies to treat them.
Seed: Primary tumor microenvironment
Tumors can impact the immune response through manipulation of metabolites and stromal 
components in their microenvironment. One way this is done is through overexpression of 
IDO, an enzyme that metabolizes tryptophan to kynurenine, effectively depletes tryptophan 
in the microenvironment [18]. Depletion of tryptophan activates a stress response in T–cells 
that inhibits their proliferation and induces an immunosuppressive Treg phenotype [19]. 
Additionally, the release of kynurenine in this process further promotes Treg differentiation, 
as well as an immunosuppressive phenotype in the professional antigen presenting cells 
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(APCs), DCs and macrophages, causing them to secrete more regulatory cytokines such as 
IL–10 and TGFβ [19].
Stromal components also inhibit an effective antitumor immune response. The tumor stroma 
consists of fibroblasts, specialized mesenchymal cells distinct to the tissue environment, 
vascular endothelial cells, pericytes, and extracellular matrix (ECM) components. These 
components not only provide a physical barrier to entry by immune cells, they also actively 
suppress the immune system by impeding antigen presentation to T–cells [20]. Fibroblasts 
also have a role in tumor progression and metastases, secreting tissue growth factors that can 
promote tumor growth and matrix metalloproteases (MMPs) that can degrade the ECM and 
promote growth, invasion, angiogenesis, and metastasis [21]. Lastly, mesenchymal stromal 
cells can produce TGF–β and soluble decoy T–cell ligands that dampen the immune 
response and impede T–cell contact with tumor cells [22].
Involvement of immunosuppressive immune cells
Counter regulatory mechanisms, normally used to resolve an inflammatory response are 
taken advantage of by tumors, allowing immune evasion and promoting their survival. 
MDSCs, immunosuppressive cells from an immature myeloid lineage, are induced by 
inflammation and necrosis within the TME and have multiple ways of downregulating the 
antitumor immune response [23]. These cells deplete amino acids in the TME, starving T–
cells and inhibiting signaling pathways required for their activation (Figure 2) [24]. They 
also produce nitric oxide (NO) through expression of nitric oxide synthases (NOS2 and 
NOS3), which inhibits IL–2 signaling and T–cell activation [24]. Reactive oxygen species 
(ROS) are also produced, damaging proteins, lipids, and nucleic acids and enhancing 
apoptosis of T–cells. Furthermore, the ROS react with NO forming peroxynitrite, which 
nitrosylates TCRs and MHCs, disrupting their interaction and rendering cancer cells 
resistant to cytotoxic T–cell responses [24]. MDSCs also express the regulatory cytokine IL–
10 and TGF–β, inducing Tregs and M2 polarized, immunosuppressive macrophages [24].
Tumor associated macrophages (TAMs) also contribute to immunosuppression within the 
TME. In general, macrophages maintain one of two polarization states: M1 and M2. M1 
macrophages contribute to a classic Th1 response, producing inflammatory mediators 
directed against pathogens and tumor cells, while M2 macrophages contribute to 
immunosuppression and repair. Tumor associated macrophages (TAMs) take on a pro-
tumoral M2 phenotype, producing factors involved in growth, extracellular matrix 
remodeling, angiogenesis, and immunosuppression [25]. Multiple tumor-derived factors 
drive the recruitment of these macrophages including VEGFA, CCL5, CCL9, CCL18, 
CCL2, and CSF1 [25–27]. The tumor-promoting role of TAMs is illustrated by the finding 
that high CSF concentrations in tumors is associated with poor prognosis in breast cancer 
patients [26]. These TAMs are poor antigen presenting cells, expressing HLA–G and HLA–
E, inhibitory MHC–I molecules that inhibit NK cell and T–cell lysis [27]. They also 
contribute to the immunosuppressive TME through the expression of co-inhibitory 
molecules PD–L1 and PD–L2, IL–10, TGFβ, and chemokines (CCL5, CCL20, and CCL22) 
that act to recruit Tregs within the TME [27–29]. Additionally, they are highly involved in 
Leibold et al. Page 4
Curr Neurobiol. Author manuscript; available in PMC 2019 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
the processes of metastasis through extracellular matrix remodeling (TGF–β, MMP–2, 
MMP–9, LL37, SR–A, Cathepsins) and angiogenesis (VEGF, PDGF) [25,27].
Dendritic cells, the most potent professional APCs, are often divided into 2 main subsets: 
myeloid dendritic cells (mDCs, CD11c+) and plasmacytoid dendritic cells (pDCs, CD11c–) 
[30]. The mDCs are present in non-lymphoid tissues, and normally promote a Th1 T–cell 
response through the expression of IL–12. Conversely, pDCs are present in secondary 
lymphoid organs, and classically produce IFN–α in response to viral infections [31]. DCs 
can be further classified as mature or immature, with immature DCs showing decreased co-
stimulatory molecule and cytokine expression, leading to a more immunosuppressive 
phenotype [30]. DCs in the TME tend to be more immature, as the TME inhibits their 
differentiation [32]. This decreases their ability to present tumor antigens to T–cells and 
provide the necessary co-stimulation, while actively suppressing the anti-tumor immune 
response through the expression of IL-10 and TGFβ and subsequent promotion of Tregs 
[32,33]. Additionally, pDCs that are recruited into tumors express a more tolerogenic 
phenotype, producing IDO and ICOSL, favoring Treg recruitment [31,33]. These pDCs, 
normally potent IFN-α producers, are poor type I IFN producers in the TME, due to the 
influence of TGF–β and TNF–α expressed by the tumor cells [31]. They also suppress T–
cell proliferation in the TME through the production of granzyme B [31,34]. Notably, pDCs 
are able to promote anti-tumor immune responses if they are properly stimulated, making 
them a desirable target for immunotherapies, but the inhibitory nature of the TME induces a 
pro-tumoral pDC phenotype [31].
The last major cell type involved in creating the immunosuppressive TME is the regulatory 
T cell. Normally vital to immune homoeostasis and induction of tolerance to self-antigens, 
these cells are potent regulators of the immune system within the TME. They accomplish 
this immunosuppression through a variety of mechanisms. They release copious amounts of 
regulatory cytokines (IL–10, IL–35, and TGFβ) while expressing numerous co-inhibitory 
receptors (CTLA–4, PD–1, LAG–3, TIM–3, ICOS, TGIT), and they consume IL–2 in the 
TME [35]. This prevents the activation of Th1 T–cells and suppresses the antitumor immune 
response. Furthermore, these cells can be directly cytotoxic to immune cells through the 
production of perforin and granzyme [35].
Transit (Seed to Soil): Intravascular Microenvironment
Once metastatic tumor cells break free from the primary tumor and enter circulation, they 
face a new set of challenges in the circulation. Mechanical stress is constantly threatening 
the circulating tumor cells (CTCs) in the form of sheer forces due to blood flow, and 
compression when entering small capillaries [36]. Tumors combat this through the formation 
of cell-platelet and cell-cell microaggregates, making them resistant to mechanical stress 
[36]. Additionally, through inhibition of the apoptotic signaling pathways these cells not 
only resist mechanical stress-induced apoptosis, but apoptosis as a result of loss of integrin 
signaling [36]. Overexpression of the transmembrane protein pannexin-1 inhibits apoptosis 
induced by mechanical stress [37], and activation of pro-survival pathways like PI3K/Akt 
counteract the apoptotic effects of integrin signaling loss [38].
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In addition to resisting apoptosis induced by a drastic change in environment, the CTCs 
must avoid immune cell recognition. This is more difficult than in the cells’ 
immunosuppressive primary tumor environment, as the circulation contains numerous 
peripheral immune cells primed for surveillance. Here platelets also play a role, shielding 
the CTCs from immune recognition [36]. The role of platelets goes beyond physical 
shielding of the tumor cells though, they also directly inhibit NK cells through expression of 
TGF–β, downregulating NKG2D on NK cells [39]. CTCs themselves can avoid recognition 
by NK cells through cleavage of MICA and MICB on their surface, NKG2D ligands used by 
NK cells to recognize and kill tumor cells [40]. Lastly, platelets can transfer normal MHC 
class I molecules to the surface of tumor cells, shielding them from cytotoxic T–cells [41].
In addition to platelets, macrophages play an essential role in protecting CTCs. Platelets and 
fibrin around CTCs recruit macrophages, which are a required component for the survival of 
the tumor cells in circulation [42]. One proposed mechanism through which macrophages 
enhance CTC survival is through expression of α4–integrin, interacting with VCAM–1 on 
the CTC surface and providing a survival signal [43]. The macrophage-CTC interaction is 
not only important in intravascular survival of CTCs, it is involved throughout the entirety of 
the metastatic cascade. CTCs induce a macrophage phenotype that promotes intravasation of 
tumor cells from the primary tumor [44]. Furthermore, macrophages facilitate extravasation 
and colonization of CTCs in distant sites [42,45].
Soil: Development of Metastatic Niche
Once a tumor cell has released itself from the primary tumor, invaded the surrounding 
stroma, crossed the endothelial barrier into the systemic circulation, and made its way to the 
vessels in the brain, it arrests in microvasculature at vascular branch points. The physical 
limitations of the tumor cells within small vessels facilitates the formation of attachment 
points between the endothelium and the cell [46]. These attachment points are formed using 
interactions between selectins, integrins, cadherins, CD44, and ICAMs/VCAMs [46,47]. 
Exactly which receptors and linkages are used is highly complex, and depends on the 
vascular bed, the type of cancer cell, and interactions with a multitude of cell types within 
the microenvironment [46].
Once attached, the metastatic cell must migrate through the endothelial cell junction. 
Breaking down these junctions involves the destruction of junctional adhesion molecules, 
occludins, and claudins by proteolytic enzymes like seprase and cathepsin S [48,49]. After 
breaking through the endothelial barrier, the metastatic cells encounter the basement 
membrane. Breakdown of this barrier is similar to the mechanisms used by the cell to break 
from the primary tumor [46]. After BBB invasion it is thought that instead of moving into 
the brain parenchyma, these cells grow along the microvasculature, a propensity known as 
“vascular cooption” [50]. This is crucial for the establishment of microcolonies. Interactions 
between integrins on the metastatic cells and the vasculature basement membrane provide 
the growth and survival cues needed for the new metastatic tumors to grow [50].
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Role of immune cells in establishing brain metastasis
It has been questioned whether resident immune cells in the brain contribute to or combat 
the establishment of BMs. On one hand, around 99% of metastatic cells that enter the brain 
fail to grow and form macrometastases [51], indicating that there are antagonistic processes 
inhibiting their establishment. On the other hand, studies have shown that resident immune 
cells can contribute to a favorable microenvironment, allowing the colonization of new BMs 
[52–59] (Figure 3). Microglia, both the resident immune cells of the brain and bone-marrow 
derived monocytes/macrophages in the perivascular spaces, are both facilitators and 
antagonists to the formation of BMs. Studies have illustrated their ability to combat and lyse 
tumor cells using NO and shown that upregulating factors like the neurotrophin NT–3, a 
regulator of microglial cell activation, is associated with increased BM formation [60,61]. 
This would suggest that microglia are protecting the brain from metastatic cell colonization. 
However, despite these antitumor mechanisms, microglia have proven to be a driving force 
in the formation of BMs. Metastatic cells use the cytoplasmic processes of microglia to 
guide their invasion into the brain [56]. Imaging has revealed the presence of a dense wall of 
microglial cells at the interface between BMs and the brain parenchyma [52]. Additionally, 
metastatic cells may modulate the function of microglia. Activated microglia normally 
produce iNOS and TNF–α, allowing them to lyse target cells [54], but in the presence of 
BMs microglia show reduced expression of these factors, suggesting the adoption of a 
polarized M2 macrophage phenotype that facilitates tumor cell proliferation and suppresses 
cytotoxic functions [54].
Astrocytes play a similar role in the facilitation of BM colonization. Xing et al showed that 
brain metastases express high levels of IL–1β under the influence of surrounding astrocytes, 
which leads to increased Notch signaling in cancer stem cells, promoting their stemness and 
growth in the metastatic niche [59]. Evidence has also shown the formation of gap junctions 
between astrocytes and tumor cells that allows for the passage of cGAMP, which activates 
the STING pathway in astrocytes and promotes expression of IFNα and TNFα to further 
facilitate tumor growth [53]. The production of ECM-degrading factors like heparanase and 
matrix metalloproteinases (MMPs) by astrocytes also contributes to invasion of BMs by 
promoting migration of these cells [55,57]. Overall, these cells that normally protect the 
brain from foreign invaders end up facilitating the entry and colonization of the brain by 
metastatic cells.
The primary tumor is also able to influence the immune composition of the premetastatic 
soil, facilitating the entry and survival of metastatic tumor cells. Liu et al. showed in a 
mouse model of breast cancer brain metastasis that a primary breast tumor can induce the 
presence of CD11b+Gr1+ myeloid cells in the brain, who in turn express the inflammatory 
chemokines S100A8 and S100A9 that are able to attract tumor cells to the brain [62]. Not 
only do these myeloid cells induced by the primary tumor have the ability to attract tumor 
cells to the brain, they can also contribute to their survival. Reports have shown high 
expression of CCL9 in the same CD11b+Gr1+ myeloid cells in the premetastatic lungs of 
mice with breast cancer and melanoma. This CCL9 expression contributed to tumor cell 
survival and metastasis in a TGF–β-dependent manner [63]. In addition to myeloid cells, 
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mast cells have also been shown to contribute to the establishment and survival of BMs, 
through expression of IL–8, IL–10, VEGF, and MMP2 [64].
Tumor Specific Metastasis Mechanisms
Although, there are several steps of the metastatic cascade that are common to all cancer 
types, there are unique properties of certain types of cancers that renders them more 
susceptible to form brain metastasis compared to others.
Breast
Of the three subtypes of breast cancer, the HER2-positive and triple-negative subtypes 
(human epidermal growth factor receptor 2 and estrogen receptor/progesterone receptor/
HER2 negative) are the most aggressive and likely to metastasize to the brain. Having a 
triple-negative cancer portends the worst survival, in part because of the increase tendency 
for brain metastasis these patients [65,66]. Almost half of the patients with advance triple-
negative breast cancer develop brain metastases. Based on the pre-clinical studies this 
phenomenon has been attributed to triple-negative breast cancer induced disruption of the 
BBB and migration of tumor cells in the brain parenchyma [67,68]. It has been postulated 
that during the metastasis process, breast cancer cells (BCC) undergo epithelial-to-
mesenchymal transition to enter the blood stream and then reverse the process with a 
mesenchymal-to-epithelial transition after arriving at brain tissue to form metastases [69]. 
Evasion of the immune defenses while in the blood stream must also occur for BCCs to 
make it to the brain vasculature. Racila et al demonstrated that single nucleotide 
polymorphism variations in C1qA, a subunit of the C1 complex, which recognizes immune 
complexes and initiates the classical pathway of complement activation, were associated 
with increased metastasis to the brain, bone, and liver in breast cancer patients. Although 
this polymorphism has comparable incidence in the normal population without breast 
cancer, patients that had breast cancer with distant metastases were more likely to have the 
SNP than those with non-metastatic breast cancer, indicating that the ability to evade 
opsonization by inhibition of complement activation has a role in spread to distant sites [70].
Once in the vasculature, BCCs upregulates surface cathepsin S expression that facilitates 
crossing of the BBB through lysis of JAM–B, a key component of tight junctions. This 
phenomenon has also been observed in primary breast tumors that have spread to the brain, 
not solely in BMs [49]. Another protein that is upregulated in triple negative breast cancer as 
well as lung adenocarcinoma and is linked to poor prognosis is mesothelin. A positive 
correlation was observed between detectable IFN-gamma in response to mesothelin and 
increased survival in whole blood analyses of patients with epithelial cancers (lung, breast, 
ovarian, melanoma), suggesting that mesothelin is an important tumor-associated antigen in 
brain metastases [71].
BCCs can manipulate microglial activation through expression of neuronal proteins. When 
expressed on the surface of BCCs, NT–3 promotes the formation of macroscopic lesions in 
the brain. It appears to play a key role in the switch back to an epithelial phenotype, allowing 
the BCCs to survive in the brain parenchyma after having invaded the abluminal basement 
membrane. Additionally, NT–3 encourages the proliferation of BCCs in the brain as shown 
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in mouse models with injected human tumor cell lines [61]. Immunomodulation by NT 3 
occurs via inhibition of microglia activation. Low levels of microglial activation promote 
growth of metastatic tumors whereas high levels of activation result in cytotoxicity 
[54,61,72]. CXCR4 signaling, which also activates microglia, has been found to facilitate 
invasion of BCC in a mouse model [73]. Differential activation of microglia can induce 
different helper T cell responses. Investigations of Th2-mediated immune responses within 
breast cancer have revealed its role in permitting BM growth. Thymic stromal lymphopoietin 
(TSLP) is a cytokine that mainly promotes a Th2-mediated immune response; depletion of 
this cytokine resulted in smaller primary tumors yet larger BM burden [74], suggesting that 
inhibiting the Th2 response may prove useful in treating BMs from breast cancer.
Melanoma
Patients with regionally advanced melanoma, including regional lymph node involvement 
and those with unknown primaries, are at a significantly increased risk for CNS 
involvement; as high as 15% of these patients will have BMs [75]. CCR4 (chemokine 
receptor 4) is expressed on melanoma cells and has increased expression in metastatic 
melanomas as compared to primary melanoma. Additionally, ligands for CCR4 (CCL17 and 
CCL22) are expressed by astrocytes, microglia, and brain endothelial cells under stress 
conditions and when exposed to melanoma-derived supernatants. In their mouse model, 
Klein et al also found that CCL17 was significantly upregulated 10 weeks post-inoculation 
of melanoma cells but before any intracranial micro-metastases were detectable, indicating 
that cutaneous melanoma has a long-distance mechanism which induces upregulation of 
CCL17, which acts as a chemoattractant to melanoma expressing CCR4+ [76]. CCR4 is also 
expressed by Th2 cells and Tregs [77] and acts as a chemoattractant for the T–cell 
populations. This induces tolerance via astrocytic, microglial, and brain endothelial 
expression of CCL17, and could be another mechanism through which metastatic melanoma 
evades the immune system. Another possible contributing mechanism of melanoma 
metastasis was found by Kaur et al. They saw that aging fibroblasts secreted increased 
amounts of sFRP2, a Wnt antagonist, which ultimately led to an attenuated response to DNA 
damage in melanoma cells, making them more resistant to vemurafenib, and drove their 
metastasis [78].
Axitinib, an inhibitor of VEGFR–1, 2, & 3, which induces a response in roughly 20% of 
those patients treated, was found to increase the number of tumor-infiltrating immune cells 
(CD45+) in an intracranial melanoma mouse model. Specifically, the sub-population of 
monocytic myeloid derived suppressor cells (moMDSCs – CD11b+Ly6ChighLy6G–) was 
increased in the intracranial tumors. These cells were found to have a reduced capacity for 
immune suppression in both intracranial and extracranial tumors but had acquired an 
antigen-presenting phenotype only in the subcutaneous tumors [79]. Another study found 
that once metastatic melanoma reaches the CNS it become significantly more tolerogenic 
than equivalent tumors in the periphery, an effect mediated by an increase in circulating 
TGF–β [80].
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Lung
Brain metastases from lung cancer are associated with dense accumulations of activated 
microglia that demarcate the boundary between tumor and adjacent brain tissue. In vitro 
studies, show that dual functions of microglia exist – protective versus cytotoxic responses. 
When different concentrations of LPS-activated (lipopolysaccharide) microglia supernatant 
were applied to metastatic lung cancer cells, the cancer cells behaved differently. At lower 
concentrations, the cancer cells had increased viability; at higher concentrations, viability 
decreased [54]. In this model both the activation and inactivation of microglia has been 
observed; increases in numbers as well as transformation to amoeboid/activated shape seen 
suggest activation while a lack of inducible nitric oxide synthase (iNOS) or TNF-alpha 
(tumor necrosis factor alpha) expression suggest that inactivation occurs simultaneously 
within tumor microenvironment [54]. Other studies confirm the presence of increased 
amounts of peritumoral microglia accumulation in NSCLC brain metastases as compared to 
melanoma brain metastases, however there is relatively little expression of iNOS and other 
enzymes involved in free radical production, suggesting that many of these microglia are 
either inactive or are supportive of the tumor [81]. Sparse T–cell and B–cell infiltrates found 
within brain metastases suggest that these cells are secondarily recruited and are not 
necessarily antigen-specific [81]. McGranahan et al found that metastatic squamous cell 
lung cancers had decreased expression of many HLA class I genes as well as decreased 
expression of components of the MHC class I molecule, suggesting that the metastatic 
tumors directly evade the immune system by decreasing the chances of successful T–cell 
activation [82]. Additionally, recent studies have shown that NSCLC BMs, despite have a 
higher mutational burden, contain fewer T–cell clones than their primary tumor counterparts, 
and the majority of the T–cell clones that were found in the BMs differed from those in the 
primary tumor [83]. This suggests not only a change in tumor immunogenicity following 
metastasis, but also highlights the ability of the blood brain barrier to inhibit immune 
responses in the CNS. Mast cells (MCs) have also been found in human BMs (via tryptase 
staining) with lung, renal, and breast origins. MCs support BM propagation via secretion of 
immune suppressive cytokines IL-8, IL-10, as well as VEGF and MMP2 [84] that modulate 
the microenvironment and contribute to metastatic potential in lung cancer patients.
Colon
Metastasis to the brain is a rare complication of CRC, and thus research on the treatment and 
mechanisms of this metastasis is sparse. Most metastatic colorectal cancer patients develop 
brain metastases as a late step in the course of the disease and it is associated with poor 
overall prognosis [85]. With significant improvements in the management of colorectal 
cancer, the incidence of metastases at previously uncommon sites is suspected to rise [86]. 
C–X–C chemokine receptor type 4 (CXCR4) and the placental enzyme indoleamine 2, 3-
dioxygenase (IDO) have both were found to be upregulated in some colorectal carcinoma 
(CRC) brain metastases. CXCR4 along with its ligand CXCL12 is involved in lymphocyte 
trafficking via chemotaxis and its upregulation in CRC has been associated with worse 
survival. IDO is important in suppressing the maternal T–cell response against the fetus and 
when observed in primary CRC predicts the formation of distant metastases [87], but 
otherwise the mechanism by which these two proteins confer worsened survival is unknown. 
Recent investigations into BM from CRC have otherwise neglected the immune system’s 
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role and have instead focused on the robust connection between the oncogenes in RAS 
family [88–90].
Immunotherapy for Brain Metastasis
Over past several years immunotherapy has emerged as an effective and robust strategy in 
the treatment of primary cancers such as lung, melanoma, renal and others [91–94]. Given 
the prominent role played by the immune system at every step of brain metastasis formation, 
there has been great interest in targeting the immune system to treat brain metastasis. Many 
patients with metastatic melanoma and metastatic lung cancers, were reported to have better 
survival after treatment with immunotherapies; these successes with nivolumab, ipilimumab, 
and pembrolizumab have improved the outlook for patients with certain metastatic cancers 
[94–97]. Until recently the clinical trials involving these medications excluded patients with 
brain metastasis, thus their effects on metastatic brain lesions is largely unknown. The 
immunotherapy strategies investigated to date include targeting the receptors on T–cells 
which are required for their activation and inhibition with monoclonal blocking antibodies 
[95,96], blocking the corresponding ligands on tumor cells and antigen-presenting cells 
[98,99], administering immune system-activating cytokines such as IL–2 [100], and tumor 
vaccines [101–104]. Table 2 outlines the current clinical trials that are evaluating 
immunotherapies for the treatment of brain metastasis.
Immune checkpoint inhibitors
Blockade of cytotoxic T-lymphocyte antigen 4 (CTLA–4) in metastatic melanoma has 
shown great promise in extracranial melanoma metastases by extending survival [94] and is 
in clinical trials for patients with BM. Expressed on Tregs, CTLA-4 binds to CD80 and 
CD86. It is in direct competition with CD28 (a T–cell co-stimulatory molecule) and induces 
T–cell anergy or suppression, thereby producing immune tolerance. In the tumor 
environment this can be critical for survival. Synder et al created a bioinformatic tool to 
evaluate binding of exomic mutations with MHC class I molecules in patients with 
metastatic melanoma treated with ipilimumab and generated a 101-tetrapeptide signature 
that confers benefit from CTLA–4 blockade [105]. These neoepitopes did not result from a 
high mutational load as the amount of mutations did not correlate with benefit from CTLA–
4 blockade. Many of these epitopes were homologous to bacterial and viral antigens already 
present in the Immune Epitope Database, suggesting that the patients who will benefit best 
from anti-CTLA–4 therapy are those whose tumors express epitopes similar to antigens 
already recognized by T–cells [105]. Interestingly in contrast to melanoma BM, there is no 
CTLA–4 expression on TIL in breast cancer BM; however, breast BMs commonly express 
PD–L1 and PD–L2 [93]. As breast cancer has not been typically thought of as an 
immunogenic cancer, these findings suggest that there is an untapped well of potential for 
therapy with immune checkpoint inhibitors.
PD–ligands transmit an inhibitory signal when binding to PD–1 receptors on T–cells, 
leading to reduced proliferation and apoptosis. The PD–1 antibodies pembrolizumab and 
nivolumab have been approved for advanced melanoma and nivolumab has been additionally 
approved for metastatic NSCLC [95–97]. Studies of metastatic tumor expression of PD–L1 
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have found that melanoma BM express lower levels of PD–L1 as compared to the primary 
tumor and extracranial metastases. The brain also has lower CD8+ T–cell content than other 
areas of metastases. Higher PD–L1 expression and T–cell content is associated with 
improved survival in melanoma [98]. In addition to variability in PD-L1 expression and TIL 
density seen in extracranial versus intracranial tumors, levels of PD-L1 expression differ 
between types of melanoma; with only 10% of uveal melanomas expressing PD–L1, while 
expression is seen 62% of chronic sun damaged melanomas [106]. This may account for the 
variability in response rates of melanoma to checkpoint inhibitors. Others have demonstrated 
that renal carcinoma BMs also have high amounts of CD8+ lymphocytes, similar to 
melanomas but Foxp3+ cells (Tregs) are found in rather low quantities in all tumors [99]. 
These findings suggest that expansion of the indications for immune checkpoint inhibitor 
therapy may be warranted; further investigation will need to be done to determine the 
viability of these therapies in other cancers with BMs. Furthermore, biomarkers of response 
to these checkpoint inhibitors are needed to predict which patients will benefit from these 
therapies. Some suggested markers have been the tumor’s mutational load or the burden of 
copy number loss, which have been shown to be correlated with clinical outcomes in 
patients treated with PD-L1 and CTLA-4 inhibitors [107,108].
Another factor in the use of checkpoint inhibitors is their interaction with the human gut 
microbiome. Recent studies have shown significant differences in the micriobiome of those 
patients who responded to therapy and those who did not. The responders had higher alpha 
diversity, a significantly larger population of Ruminococcaceae, and an enrichment of 
anabolic pathways, all leading to more favorable antitumor immunity [109]. Additionally, 
this phenotype could be reconstituted in germ free mice through a fecal transplant. Another 
study found that the microbiomes of metastatic melanoma patients who responded to anti-
PD-L1 therapy were richer in Bifidobacterium longum, Collinsella aerofaciens, and 
Enterococcus faecium compared to non-responders; and again the improved anti-tumor 
immunity and greater efficacy of anti-PD–L1 agents seen in these patients could also be seen 
in germ free mice who received a fecal transplant from them [110]. These studies suggest 
that it is possible to enhance a patient’s response to immune checkpoint inhibitors through 
modification of their microbiome.
Tumor vaccines for brain metastasis
Most vaccines are used prophylactically to induce an adaptive immune response against a 
specific antigen, usually antigens present on pathogens one wants to protect against. 
However, in the case of using vaccines against tumors the goal is to induce a therapeutic 
adaptive immune response, as opposed to a prophylactic one. Multiple vaccine types have 
been proposed as candidates to treat intracranial tumors: peptide vaccines, adoptive T–cell 
transfer, and DCs primed with tumor antigens are the major examples. These strategies have 
been extensively investigated for the treatment of high grade gliomas and glioblastomas, yet 
not so for brain metastases [111]. In the context of glioblastoma, a large phase III clinical 
trial showed that addition of an autologous tumor lysate-pulsed dendritic cell vaccine to be 
safe and may increase overall survival [112]. In the context of other cancers, the exclusion 
criteria for patients enrolled in trials employing vaccination strategies for other malignancies 
usually preclude the enrollment of patients with CNS involvement [113]. Though the 
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existence of large trials employing vaccines against BMs is lacking, there have been a few 
select case reports and small clinical studies performed.
Peptide vaccines induce an antitumor immune response by being taken up by APCs and 
being presented to T–cells, which then travel to the brain to recognize and kill the tumor 
cells based on the antigen presented. One group recently used peptides from IDO and 
survivin to vaccinate melanoma patients in a phase II study, in combination with TMZ. The 
study was done in 17 patients, 8 of which had brain metastasis, and their results showed a 
clinical benefit in 18% of the patients, assessed by PET–CT, with one patient showing tumor 
regression [114]. While the clinical benefit of this study was underwhelming, the peptide 
vaccine was able to induce vaccine-specific immune responses. Peptide vaccines still face 
multiple challenges that researchers are attempting to overcome. Unfortunately, tumor 
heterogeneity and antigen selection lead to the proliferation of tumor cells without the 
antigen being vaccinated against. This mechanism of resistance is being addressed by next-
generation multi-peptide vaccines [115]. An additional challenge is inducing a sufficient 
immune response to generate the necessary number of activated APCs and subsequent anti-
tumor T–cells [115].
DC vaccines have also been used with some success. They are formed by isolating a 
patient’s own DCs, electroporating them with mRNA of the antigen(s) of interest, expanding 
and activating these cells, and then injecting them back into the patient, where they can 
travel to lymph nodes and activate antitumor T–cells. These vaccines have the advantage of 
activating the APCs ex vivo, leading to more sufficient activation than seen in peptide 
vaccines. Additionally, unlike peptide vaccines, DC vaccines have shown the ability to 
evolve alongside the tumor and increase the diversity of antigens presented over time [116]. 
In one study of 12 patients with metastatic renal cell carcinoma, one patient with four brain 
metastases demonstrated a complete and durable regression after being treated with a DC 
vaccine [117]. Success was also seen in a phase I/II trial where 20 patients with metastatic 
melanoma, 3 with BM, were treated with DCs incubated with irradiated melanoma cells and 
GM-CSF [118]. They achieved an overall survival rate of 95% at a median follow-up of 13.8 
months and reported one case in which a woman with a BM remained in remission 36 
months after starting the therapy. In a follow up randomized phase II trial by the same group, 
42 patients with melanoma were randomized to DC vaccine vs. tumor cell vaccine and 
followed for 5 years. Their results showed that patients treated with DC vaccine had 70% 
reduction in the risk of death and double the median survival [119]. The difficulties in using 
DC vaccines lies in the localization of DCs to lymph nodes; only a small fraction make it to 
a lymph node to present the antigen and there are barriers to entry and presentation from the 
CNS lymphatics and BBB [115]. However because of biological heterogeneity and neo-
antigens resulting from each patient’s cancer mutational landscape, autologous tumor 
derived tumor associated antigen loading of DCs has the potential to induce a more diverse 
and effective anti-tumor immune response. It is clear that DC vaccines are able to exert an 
anti-tumor effect in the CNS in people with BMs, but larger trials looking exclusively at 
patients with BMs are needed.
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Combined Stereotactic Radiosurgery and Immunotherapies for Brain 
Metastases
One question that arises in the implementation of immunotherapies to treat BMs is how they 
interact with the current standard of care; in the case of brain metastases this is stereotactic 
radiosurgery (SRS). Systemic radiation is thought to be antagonistic to immune therapies, as 
it inhibits the proliferation of peripheral immune cells and induces lymphopenia [120]. 
However, with the advent of SRS, a more concentrated, focal dose of radiation can be 
delivered to a tumor bed and can not only have an antitumor effect at that site but also at 
distant metastatic sites not targeted by radiation; a phenomenon known as the abscopal effect 
[121]. It is thought that this effect is primarily immune mediated [122], as radiation is able to 
increase antigen availability and visibility as well as activate important immunostimulatory 
pathways like cGAS-STING [123]. The immune modulatory effects of SRS suggest that 
there is an opportunity for synergism between these two modalities.
In 2012 Knisely et al. published a retrospective analysis of 77 patients with melanoma BMs 
who had received SRS and showed significant improvements in the median survival of 
patients who had also received the CTLA–4 inhibitor Ipilimumab, from 4.9 months to 21.3 
months [15]. The benefits of combined SRS and immunotherapies for melanoma BMs has 
been subsequently confirmed in multiple studies [124–126], and some have even shown their 
treatment with SRS and immune checkpoint inhibitors to be superior to SRS and 
chemotherapy or BRAF/MEK inhibitors [127,128]. In addition to melanoma, concurrent 
SRS and systemic immunotherapy has also shown a benefit in the treatment of NSCLC BMs 
[129,130]. Studies are needed to investigate if this benefit may also be conferred in those 
patients with BMs from breast, renal, and colon cancers.
Future of Immunotherapy in Brain Metastasis
With the recent success of the combined ipilimumab and nivolumab trials, it appears 
checkpoint inhibitors will remain at the forefront of immunotherapy in the treatment of 
BMs. Besides the massive success these antibodies have shown, they are also technically and 
logistically more feasible in the treatment of BMs. Premade antibodies that can be stored en 
mass have a distinct benefit over culturing and expanding DC or T–cell populations, or even 
in producing patient-specific peptides for vaccination. Even though with limitations, tumor 
vaccines can be optimized to increase their efficacies. Development of an adaptive immune 
response is a slow process, which makes it difficult to use when trying to outpace the growth 
of the tumor. This does not mean that these approaches are ineffective though. Multiple 
studies have demonstrated their efficacy and feasibility and it is likely that in the future the 
active immunization could be used in concert with the passive antibody treatments.
Using these therapies in combination provides a distinct benefit and likely reduces the 
probability of escape variants. In the future, immunotherapies for brain metastases will 
likely be used like treatments for HIV: using 4 or 5 different drugs at once that all target 
discrete mechanisms, making it harder for the resistant variants to emerge. The challenge 
will be mitigating the effects of immune overactivation in the CNS, which is known to have 
devastating side effects itself. There is also the advent of exciting new technologies on the 
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horizon. One exciting development is the advent of so called “Y–traps,” checkpoint 
inhibitors fused to a TGFβ receptor domain. This allows for a single molecule to 
simultaneously block checkpoint inhibition, while removing the inhibitor molecule TGFβ 
from the TME. This combinatorial effect, combined in a single molecule, allowed for greater 
inhibition of Tregs and greater antitumor response than seen with PD–L1 inhibitors alone 
[131]. It will be interesting to see in the future if this bifunctional antibody approach can be 
used on other immune regulators or expanded to target an even greater number of molecules 
at once.
Besides the development of new therapies, there is also currently an attempt to improve the 
existing therapies. One way this is being done is through the development of biomarkers that 
will accurately predict which patients will respond to specific immunotherapies. Exploring 
new immune markers like PD–L1 with immunohistochemistry, the assessment of mutation 
load and microsatellite instability, the characterization of TILs, and the gene expression 
profiles of tumors all serve as ways to parse out who will best respond to which 
immunotherapies [132].
Conclusion
Cancers that metastasize to the brain have mechanisms to avoid immune detection and 
subvert the immune system for their own benefit. They alter T–cell ligand and co-
stimulatory molecule expression, activate and suppress microglia, activate macrophages, 
secrete anti-inflammatory cytokines, downregulate proteins needed for antigen presentation, 
and upregulate angiogenic factor expression. The brain microenvironment provides an 
interesting context to the above changes: astrocytes prevent microglial activation from 
getting out of control in the setting of injury as well as during metastasis growth and yet 
some microglia have been implicated in promoting tumor growth as opposed to being too 
weak to impede it. Specific cancers have been found to have some differing mechanisms of 
metastasis to the brain and some that are shared between a few individual types. So far there 
has been no one underlying mechanism that explains all metastasis to the brain. 
Macroscopically, multiple different mechanisms combine in each type of primary cancer to 
produce the same result; further studies will delineate the differences and commonalities 
between mechanisms of various cancer types. Better and more precise understating of the 
metastatic process and host immune system will open the door for development of 
successful future immunotherapeutic options for BMs.
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Figure 1. Steps Involved in Brain Metastasis.
Brain metastasis cascade involves four major steps: 1) Detachment of the metastatic cell 
from the primary cancer, 2) Survival in systemic circulation, 3) Invasion in the brain 
parenchyma and 4) survival in the CNS microenvironment.
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Figure 2. Immune Cell and Tumor Cell Interaction.
Tumor cells can actively manipulate the tumor immune microenvironment by interacting 
with dendritic cells (DCs), tumor associated macrophages (TAMs), myeloid derived 
suppressor cells (MDSCs) and T cells. Overall goal of tumor mediated immune cell 
manipulation is to achieve immunosuppressive microenvironment.
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Figure 3. CNS Microenvironment of BM.
Upon invasion of the brain parenchyma tumor cells predominantly interacts with activated 
microglia and astrocytes to establish a new metastatic niche.
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Table 1.
Proportion of patients with brain metastasis at time of initial diagnosis, median survival after brain metastasis 
diagnosis, incidence of leptomeningeal disease, and metastatic pattern in patients with SCLC, NSCLC, 
adenocarcinoma of the lung, breast cancer, renal cancer, colorectal cancer, and melanoma [1,133–137].
Type
Incidence of Brain 
Metastases at Initial 
Diagnosis (%)
Incidence of Brain 
Metastases Among 
Patients with 
Metastatic Disease (%)
Median Survival 
after Brain 
Metastasis Diagnosis 
(months)
Incidence of 
Leptomeningeal Disease 
(%)
Small Cell Lung Cancer 15.83 22.43 6.0 10–25
Non Small Cell Lung Cancer 
NOS 12.81 22.56 4.0 1–3.8
Breast Cancer 0.41 7.58 10 5
Renal Cancer 1.48 10.84 5 0.03
Colorectal Cancer 0.27 1.36 6 0.058
Melanoma 0.65 28.16 6 22–46
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Table 2.
Clinical trials investigating immunotherapies in brain metastasis.
Trial Name Interventions Status Location
Improved Therapy 
Response Assessment 
in Metastatic Brain 
Tumors
Diagnostic Test: Magnetic Resonance 
Imaging
• Radiation: Stereotactic 
Radiosurgery
• Drug: Ipilimumab, 
nivolumab or 
pembrolizumab
Recruiting
• Oslo University Hospital, Oslo, 
Norway
Proteome-based 
Immunotherapy of 
Lung Cancer Brain 
Metastases
• Biological: Dendritic 
vaccine, allogeneic 
hematopoietic stem 
cells, cytotoxic 
lymphocytes
• Biological: Dendritic 
vaccine, autologous 
hematopoietic stem 
cells, cytotoxic 
lymphocytes
Enrolling by Invitation
• ZAO “NeuroVita Clinic of 
Interventional and Restorative 
Neurology and Therapy”, 
Moscow, Russian Federation
Proteome-based 
Immunotherapy of 
Brain
Metastases From 
Breast Cancer
• Biological: Dendritic 
vaccine, allogeneic 
hematopoietic stem 
cells, cytotoxic 
lymphocytes
• Biological: Dendritic 
vaccine, autologous 
hematopoietic stem 
cells, cytotoxic 
lymphocytes
Enrolling by Invitation
• ZAO “NeuroVita Clinic of 
Interventional and Restorative 
Neurology and Therapy”, 
Moscow, Russian Federation
Anti-PD 1 Brain 
Collaboration + 
Radiotherapy: The 
ABC-X Study
• Drug: Ipilimumab
• Drug: Nivolumab
• Radiation: Stereotactic 
Radiotherapy
• Radiation: Whole Brain 
Radiotherapy
Not yet recruitin
• Westmead Hospital, Sydney, 
New South Wales, Australia
• Melanoma Institute Australia, 
Wollstonecraft, New South 
Wales, Australia
• Princess Alexandra Hospital, 
Woolloongabba, Queensland, 
Australia
• Royal Adelaide Hospital, 
Adelaide, South Australia, 
Australia
• Peter MacCallum Cancer 
Centre, East Melbourne, 
Victoria, Australia
A Study of 
Fotemustine (FTM) Vs 
FTM and Ipilimumab 
(IPI) or IPI and 
Nivolumab in 
Melanoma Brain 
Metastasis
• Drug: Fotemustine
• Drug: Fotemustine and 
Ipilimumab
• Drug: Ipilimumab and 
nivolumab
Recruiting
• Medical Oncology, Cancer 
Institute “Giovanni Paolo II”, 
Bari, Italy
• Medical Oncology, Pope 
Giovanni XXIII Hospital, 
Bergamo, Italy
• National Institute for Cancer 
Research, Genoa, Italy
• Immunotherapy and Somatic 
Cell Therapy Unit, Scientific
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Trial Name Interventions Status Location
Institute of Romagna, Meldola, 
Italy
• Surgical Oncology, National 
Cancer Institute, Milan, Italy
• European Institute of Oncology, 
Milan, Italy
• Medical Oncology and 
Innovative Therapy, National 
Cancer Institute, Naples, Italy
• Esophageal and melanoma 
oncology, Istituto Oncologico 
Veneto, Padua, Italy
• Medical Oncology, National 
Cancer Institute “Regina 
Elena”, Rome, Italy
• Medical Oncology and 
Immunotherapy Unit, 
University Hospital of Siena, 
Siena, Italy
• S C Dermatology, A.O.U. City 
of Health and Science of Turin, 
Turin, Italy
Radiation Therapy with 
Combination 
Immunotherapy for 
Relapsed/Refractory 
Metastatic Melanoma
• Drug: Interleukin-2 & 
Ipilimumab (P-Ib)
• Drug: Interleukin-2 & 
Ipilimumab (P-II)
Recruiting
• Masonic Cancer Center - 
University of Minnesota, 
Minneapolis, Minnesota, United 
States
Personalized Cellular 
Vaccine for Brain 
Metastases 
(PERCELLVAC3)
• Biological: Personalized 
cellular vaccine Recruiting
• Guangdong 999 Brain Hospital, 
Guangzhou, Guangdong, China
Anti-PD 1 Brain 
Collaboration for 
Patients with 
Melanoma Brain 
Metastases
• Drug: Nivolumab
• Drug: Ipilimumab Active, not recruiting
• Melanoma Institute Australia, 
North Sydney, New South 
Wales, Australia
• Princess Alexandra Hospital, 
Woolloongabba, Queensland, 
Australia
• Royal Adelaide Hospital, 
Adelaide, South Australia, 
Australia
• Peter MacCallum Cancer 
Centre, East Melbourne, 
Victoria, Australia
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